Live Webinar: The Ultimate Cleaning Validation Audit Readiness Blueprint. Register Now

Experience Leucine AI .
‍Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /

Reagents and Standards

View Detailed Analysis

Analytics Overview

Form 483s Issued

483s converted to WL

Total Observation

Analytics Overview

Form 483 Conversion Rate by Year

Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s

Issue Date

Facility Name

Product Type

Form 483

Converted

Warning Letter

15 Nov 2024

Exela Pharma Sciences LLC

Drugs

View Form 483

Top Investigators

Investigator Name

Form 483 Count

Warning Letter Count

Joan Cantellops

Logan Williams

Megan Ziegler

Santos Camara

Observations

View all Observations

TITLE/ COMPANY	Issue Date	Status	Details
Laboratory records do not include complete records of any testing and standardization of laboratory standard solutions. Exela Pharma Sciences LLC	15 Nov 2024	Normal	Justification: The observation directly concerns the stability and suitability of laboratory resolution solutions, which fall under the management of reagents and standards. Excerpt: There is no scientific rationale to support that a resolution solution is stable indefinitely, such as continuous monitoring nor assessment of the chromatographic behavior of this resolution solution since the initial use in 2021. View Details
The calibration of instruments and recording devices is not done at suitable intervals in accordance with an established written program. Exela Pharma Sciences LLC	15 Nov 2024	Normal	Justification: Proper handling of laboratory reagents and standards ensures quality testing. The observation outlines inadequate segregation and traceability, posing contamination risks. Excerpt: Laboratory reference standards ... were not segregated from reagents and test solutions to prevent possible mix-ups and contamination. View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.

Uncover Trends: FDA Investigator profiles & Observations.

Stay Compliant: Manage risks proactively.

Reagents and Standards

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Written By

Vivek Gera

Reading Time

Minutes

ON THIS PAGE

Overview

Trends

Recent Form 483s

Top FDA Investigators

Key Observations

FAQ

Back to the Top